Evosep webinar
Plasma Proteomics
Available on demand
The use of high-throughput methods in plasma proteomics has revolutionized the field, allowing for the analysis of large cohorts of patients and the identification of hundreds or even thousands of proteins simultaneously. This approach has led to the discovery of novel biomarkers and therapeutic targets that were previously unknown.
SPEAKERS
High-Throughput Plasma Proteomics to analyze thousands of plasma samples
Talk by Arthur Viodé, Proteomics Scientist at Boston Children’s HospitalÂ
The new latest generation of proteomics hardware has enabled high-throughput proteomics. When realizing a high-throughput proteomics pipeline, robustness along the entire pipeline is a must. The Evosep ONE LC system has proven to be extremely robust enabling the analysis of thousands of plasma samples. Recent work from the Steen Lab at Boston Children’s Hospital/Harvard Medical School has proven this point when developing and deploying a plasma proteomics pipeline of unprecedented throughput and analytical depth (PMID: 36989362). Our method based on a simple precipitation step (~$2.5 per sample) was optimized and validated by processing >3000 samples with no apparent batch effect. Using this method, we were able to achieve remarkable depth of analysis, detecting >1300 proteins per run using DIA-PASEF at a throughput of 60 samples per day.
High-throughput automated Evosep MRM workflow for glycated albumin quantification in diabetes
Talk by Bharath Kumar Raghuraman, post-doc at odense university hospital and Scientist at EvosepÂ
Glycated hemoglobulin (HbA1c) is the gold standard for the diagnosis of diabetes mellitus and for assessing glycemic status in these patients. Although HbA1c faithfully represents the average blood glucose level over the previous 8–12 weeks, its utility in monitoring the effect of medical interventions and diabetes progression is limited. Because HbA1c is prone to fluctuations in conditions like diabetic nephropathy, anaemia, and pregnancy, glycated albumin has gained traction as a potential alternative due to its shorter half-life (2–3 weeks) and higher affinity to glycation. To quantify glycated albumin, we developed a high-throughput automated Evosep-MRM workflow to monitor 2 glycation sites of human serum albumin in plasma and serum.
